Contrive Datum Insights has published "Genomics Market Size, Share & Industry Analysis, By Application & technology (Real-Time PCR, Functional Genomics, Transfection, Microarray Analysis, Mutational Analysis, SNP Analysis, Epigenomics, RNA Interference, Bisulfite Sequencing, Pathway Analysis, Chromatin Immunoprecipitation (ChIP & ChIP-Seq), Bead-Based Analysis, Methylated DNA Immunoprecipitation (MeDIP), High-Resolution Melt (HRM), Chromatin Accessibility Assays), Proteomics tools (2-d page; yeast 2-hybrid studies) (Mass Spectrometry, DNA Sequencing, Biomarker Discovery, Bioinformatics, Real-time PCR, Microarray Analysis, Statistical Analysis, Others), Deliverables (Consumables & Reagents, Instruments/Systems/Software, NGS-based Services, Core Genomics Services, Biomarker Translation Services, Computational Services, Others), End-use (Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Clinical Research, Hospitals & Clinics, Other End Users), Application area (Oncology, Reproductive & Genetic Health, Agricultural & Animal Genomics, Forensic Sciences, Other Applications), and Regional Forecast, 2026-2034". The study sizes the global genomics market at USD 45 billion in 2025 and projects growth from USD 50.63 billion in 2026 to USD 129.88 billion by 2034, a compound annual growth rate of 12.5% across the forecast period.
Genomics encompasses the instruments, reagents, consumables and analytical services used to sequence, genotype and functionally characterize DNA and RNA, spanning platforms such as next-generation sequencing, PCR, microarrays and mass-spectrometry-based proteomics tools. Buyers include pharmaceutical and biotechnology developers using genomic data to guide drug discovery and biomarker-driven trials, clinical and hospital laboratories running diagnostic and screening tests, academic and government research institutes, and agricultural and forensic laboratories applying the same core technologies to non-clinical samples.
Expanding clinical adoption of next-generation sequencing in oncology and rare disease diagnostics
Expanding clinical adoption of next-generation sequencing in oncology and rare disease diagnostics is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 12.5% a year, the deliverables lines exposed to it move fastest: Computational Services compounds at 16.72%, taking its share of revenue from 5% to 7% and its value from USD 2.25 billion to USD 9.09 billion.
On the upside, the study's bull case assumes clinical reimbursement pathways for genomic testing widen faster than assumed and sequencing costs fall ahead of the historical trend, pulling forward adoption in oncology and population screening programs, which would take 2034 revenue to USD 149.36 billion rather than the USD 129.88 billion base case.
However, reimbursement expansion and regulatory clearances for clinical genomic tests move slower than assumed, and instrument capital costs stay elevated, delaying the shift of sequencing volume from research into clinical and agricultural use, which would hold 2034 revenue to USD 110.4 billion. Consumables & Reagents, which carries 34% of 2025 revenue, already grows at only 11.74% against the market's 12.5%, so the largest part of the base is also its slowest.
Key Players Compete on Consumables & Reagents Volume and Computational Services Growth
Competition in the global genomics market runs along the deliverables axis rather than the regional one. Consumables & Reagents holds 34% of 2025 revenue at USD 15.3 billion and remains the largest line through 2034 at 32%, making it the position hardest for a challenger to take. Computational Services, growing at 16.72%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 45 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Deliverables | Consumables & Reagents | 34% · USD 15.3 billion | — |
| Application & technology | Real-Time PCR | 16% · USD 7.2 billion | Bisulfite Sequencing 16.78% |
| Proteomics tools (2-d page; yeast 2-hybrid studies) | Mass Spectrometry | 24% · USD 10.8 billion | Bioinformatics 15.9% |
| End-use | Pharmaceutical & Biotechnology Companies | 34% · USD 15.3 billion | Hospitals & Clinics 15.32% |
| Application area | Oncology | 38% · USD 17.1 billion | — |
- Based on regional analysis, North America led the global genomics market in 2025 with 42% of global revenue at USD 18.9 billion, reaching USD 49.35 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 29% in 2034, with revenue growing from USD 10.8 billion to USD 37.66 billion.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 4% by 2034.
- Computational Services is projected to grow at 16.72% over the forecast period, the fastest of any deliverables line.
- The United States is the largest single country market at USD 14.74 billion in 2025, 32.76% of global revenue.
The report segments the market across five axes; by deliverables, and by application & technology, proteomics tools (2-d page; yeast 2-hybrid studies), end-use and application area; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 110.4 billion and USD 149.36 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.